With amenorrhea | Without amenorrhea | p † | OR‡ (95% CI) | |
---|---|---|---|---|
n = 26 | n = 36 | |||
Age (years) | 33 (18-45) | 30 (19-44) | 0.20 | 1.0 (1.0-1.1) |
Subjects < 40 years old | 17 (65%) | 34 (94%) | 0.005 | 9.0 (1.7-46.4) |
Subjects ≥ 40 years old | 9 (35%) | 2 (6%) | ||
Duration of SLE (months) | 5 (1-241) | 3 (1-128) | 0.77 | 1.0 (1.0-1.0) |
SLE manifestation | ||||
Nephritis | 12 (46%) | 16 (44%) | 1.00 | 1.1 (0.4-3.0) |
CNS lupus | 5 (19%) | 3 (8%) | 0.26 | 2.6 (0.6-12.1) |
Vasculitis | 2 (8%) | 4 (11%) | 1.00 | 0.7 (0.1-3.9) |
Cytopenia | 8 (31%) | 9 (25%) | 0.77 | 1.3 (0.4-4.1) |
Positive anti-SS-A/Ro antibodies | 14 (54%) | 21 (58%) | 0.80 | 0.8 (0.3-2.3) |
Positive anti-U1-RNP antibodies | 10 (38%) | 16 (44%) | 0.61 | 0.7 (0.3-1.9) |
SLEDAI-2K | 13.5 (5-31) | 11.5 (2-26) | 0.35 | 0.9 (0.9-1.0) |
Max. dose of prednisolone (mg) | 50 (25-125) | 45 (14-100) | 0.43 | 1.0 (1.0-1.0) |
Glucocorticoid pulse therapy | 6 (23%) | 6 (17%) | 0.54 | 1.5 (0.4-5.3) |
IVCY | 17 (65%) | 12 (33%) | 0.02 | 3.8 (1.3-11.0) |
Total dose of cyclophosphamide (mg) | 1300 (500-6500) | 1000 (500-2700) | 0.69 | - |
Total number of IVCY (time) | 2 (1-13) | 2.5 (1-5) | 1.00 | - |